Navigation Links
VeraLight Secures $20 Million Series C Financing
Date:6/3/2008

Plans FDA Submission of Non-invasive Diabetes Screening Device By Year End

ALBUQUERQUE, N.M., June 3 /PRNewswire/ -- VeraLight, Inc., a privately held medical device company, announced the completion of a Series C financing that will provide up to $20 million to complete the company's pivotal clinical trial, and gain worldwide commercialization and adoption of the VeraLight SCOUT DS(TM) non-invasive diabetes screening system. The current round of funding was led by the Psilos Group and CMEA Ventures, with participation by vSpring Capital, EPIC Ventures, The Dow Chemical Company, and the Southern Ute Growth Fund.

The company also announced it plans to submit a Premarket Approval application to the U.S. Food and Drug Administration by the end of this year to evaluate the safety and effectiveness of the SCOUT DS for marketing clearance.

"The financing will enable us to advance our commercialization plan and grow our global business," said David Van Avermaete, CEO of VeraLight. "Our ability to attract and maintain quality investors such as Psilos Group and CMEA Ventures is a strong endorsement of our progress to date and our strategy for building value around early diabetes detection and treatment."

Lisa Suennen, managing member of Psilos Group said, "As chairwoman and lead investor, I am excited about the prospect for VeraLight and its non- invasive spectroscopic technology to more accurately and conveniently screen people for type 2 diabetes and pre-diabetes. At Psilos we strive to support innovative science-based technologies that have a serious opportunity to combat chronic health issues such as diabetes in a high quality manner, while reducing overall costs to the healthcare system. The VeraLight SCOUT technology is well-positioned to do just that."

David Collier, MD, Managing Director of CMEA Ventures, said, "As a repeat investor, we're very excited about the clinical progress and data shown so far by VeraLight. We believe th
'/>"/>

SOURCE VeraLight, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
2. Asoyia Secures Venture Capital Funding
3. InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
6. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
7. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
8. Piedmont Pharmaceuticals Secures $8.5 Million Investment
9. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
10. UI licensee Optherion secures $37 million in financing
11. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...O, Dec. 4 Medithrive, Inc. has won...sary in the SF Bay Area by popular vote conducted ... only three months in operation, the SF Bay commun...tion for accessing medicinal marijuana. ,, Th... the obvious: a dispensary which caters to the con...
(Date:12/4/2009)...SON HEIGHTS, Mich., Dec. 4 The Edi... BetterInvesting Magazine today announced Aller...ock to Study" and C.R. Bard, Inc. (NYSE: BCR )...stors, informational and educational use. ,, "T...rtunities involving its flagship drug Botox and ot...
(Date:12/4/2009).... A new study shows that muscle cells grown in th...e shut properly. The work, performed in dogs and r...ditions such as gastric reflux and fecal incontine...sphincters, which are the bands of muscle that sep... Weakness in these areas can cause gastrointestina...
(Date:12/4/2009)... Dental tourism is a phenomenon that was started b...he high price of dental work in the US, Canada, an...d dental care, people have found that Mexican Dent...destination. , (PRWEB) De... than 6 years, Mexican Dental Vacation is seeing t...
(Date:12/4/2009)...ener Applauds Historic Effort but Points out Poten...t in Final Health Care Reform ,, NEW YORK, De...Journal of Medicine today published a Perspectiv...authored by Irwin Redlener, M.D., president, Child...r Disaster Preparedness and Professor of Clinical ...
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2
...children suffer from atopic eczema, a disease whic...d. Scientists are searching for new ways// to deve... treat the most common form of eczema. Azathio...ppressing the immune system, but it results in inc...
...etting sensitive to noise, and do not like it much...g in noisy surroundings// may face an increased ri...in Germany revealed that the chances of urban midd...ranquil surroundings. All the same, if work enviro...
...hools in sub-Saharan Africa have joined forces to ...ill allow vets to study// for postgraduate degrees...ities Veterinary E-Learning Consortium, launched i...rican vets urgently need extra training, but few h...
...ental disorders are said to account for a large po...dies have been undertaken to assess// this assumpt... part of the WHO World Mental Health (WMH) Survey ...2003, through a study called LEBANON (Lebanese Eva...
...ague Against Cancer has announced that it will be ... to bridge the gap that inadvertently// develops b...nderstanding of complex medical terminology by the...o get to know as much information as possible abou...
...icotine Quest? cigarettes seems to have lulled smo... study conducted by researchers// at the Transdisc...sity of Pennsylvania School of Medicine.Results of...for Cancer Control and Population Science at the A...
Other Medicine News:Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2
(Date:12/3/2009)...ISON, N.J., Dec. 3 A gen...of developing a potentially life-threatening blood...rapies or chemicals is one of several medical disc...est Diagnostics (NYSE: DGX ) will present during...ual Meeting and Exposition, December 5-8, 2009, in...
(Date:12/3/2009)... DIEGO, Dec. 3 BioMed Re...at it has entered into a new lease with Regeneron ...mately 131,000 square feet of additional, newly-co...ark at Eastview campus in Tarrytown, New York. The... additional space was completed approximately two ...
(Date:12/3/2009)..., HOERSHOLM, Denmark and SAN DIEGO, Califor...49 Successfully Inhibits miR-122, a microRNA Impor...gnificantly Reducing Hepatitis C,Virus in the Bloo...he,Hepatitis C Virus , - SPC3649 Demonstr... and,No Serious Adverse Events in the Treated Anim...
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5EXTRA TV Features Tosca Renos Eat Clean Diets Libido Boosting Foods 47600 1EXTRA TV Features Tosca Renos Eat Clean Diets Libido Boosting Foods 47600 2Delcath Systems Granted Third Orphan Drug Designation 12412 1Delcath Systems Granted Third Orphan Drug Designation 12412 2Delcath Systems Granted Third Orphan Drug Designation 12412 3iMedica Participates in American College of Physicians EHR Partners Program 47594 1iMedica Participates in American College of Physicians EHR Partners Program 47594 2iMedica Participates in American College of Physicians EHR Partners Program 47594 3
... Pa., Feb. 14 Until recently, it,was recommended ...,short-term antibiotics prior to receiving dental ...ditis (IE). The American Heart Association (AHA),h...s bring good news for,most cardiac patients: many ...outinely in the past no longer need them., The Am...
...lo. and MONTREAL, Feb. 14 Pharmion,Corporation (N...y announced,that the U.S. Food and Drug Administra...eacetylase (HDAC) inhibitor, MGCD0103, as an Orpha...emia (AML) in the United,States. Criteria for desi...reatment of a condition affecting fewer than 200,0...
Other Medicine Technology:New Guidelines: Antibiotic Prophylaxis 2Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
Proven™ Posterior Stabilized Knee System
Proven™ Cruciate Retaining Knee System
...sn't a new implant. It's a new material, exclusive...be greatly reduced . The nickel content is almost ...patient. Hardness, lubricity and abrasion resistan...le in our two already proven knee systems - Genesi...
...urers focus attention on implant design, one criti...e Profix Total Knee System seeks to establish a ba...e tools to implant them. Designed by Leo A. Whites...al knee instrumentation, Profix instruments are de...
Medicine Products: